

Please add the following new claims:

- 15. A method according to claim 1, wherein said iNOS gene is a NOS2A gene.
16. A method according to claim 12, wherein said iNOS gene is a NOS2A gene.--

Remarks

Applicant's attorney hereby states that the changes made in the substitute Specification and Sequence Listing do not include new matter. The Specification and Sequence Listing has been amended to conform with the proper U.S. format. Applicants have submitted an Abstract of the Disclosure under 37 C.F.R. § 1.72. Additionally, the specification has been amended to direct entry of the substitute Sequence Listing at the end of the application.


In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

Claims 3, 4, 10 and 11 have been amended to change their dependencies. Claims 3 and 7 has been amended to correct a typographical error. Support for the amendments to claims 3 and 7 may be found throughout the specification, but specifically on page 4, lines 24-25; page 6, line 15 through page 7, line 14 of the newly substituted specification. New claims 15 and 16 have been added. New claims 15 and 16 find support throughout the specification, but specifically on page 2, lines 3-6; page 4, lines 4-6 and page 7, lines 1-14 of the newly substituted specification. No new matter has been added by way of the amendments to the claims.

Entry of this Amendment into the application is respectfully requested. Applicant respectfully submits that this application is in condition for examination. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicant
Registration No. 32,893

Date: Nov. 13, 2000

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600
P:\USERS\DENISEB\1581\072pream